Up to 60 million Americans are estimated to live with depression, of them, one of three do not respond to available treatments. Enter Spravato, a nasal spray considered the biggest breakthrough drug in the battle against depression. THE FDA has approved the use of Esketamine, a relative of the intravenous anesthetic, ketamine, originally approved by the FDA in the 1970’s. This medical breakthrough has the potential to deliver immediate results. With a number of antidepressants we are used to, like Zoloft and Prozac, it takes 4 to 6 weeks to work.
Esketamine works within the first week. Marketed under the name Spravato, it is a derivative of ketamine. Our program treats depression with Esketamine, which many consider a form of powerful meditation. The better a patient gets, the less often administration needs to be done.
See if you qualify for insurance.